Tesamorelin Quick Reference (20 mg vial)

Research context: mechanisms, human and preclinical evidence, limitations and precautions are in How this works and References. The calculator (Spanish) converts any other volume.
Tesamorelin Dosage Chart (20 mg vial)
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard FDA-Approved Protocol (2 mL = ~10 mg/mL)
| Week / phase | Daily dose | Units per injection (mL) |
|---|---|---|
| Week 1 | 1 mg (1000 mcg) | 10 units (0.10 mL) |
| Weeks 2–12+ | 2 mg (2000 mcg) | 20 units (0.20 mL) |
Frequency: Once daily, subcutaneously, at a consistent time.
Reconstitution Steps
- Draw 2 mL of bacteriostatic water with a sterile syringe.1
- Inject slowly down the vial wall; avoid shaking to prevent foaming.2
- Gently swirl or roll until fully dissolved (clear solution).3
- Label with the reconstitution date and refrigerate at 2–8 °C, protected from light; use within 4 weeks.4
The per-phase amounts are identical across the Tesamorelin family. The 20 mg vial only changes the concentration, U-100 units, volume and supplies.
Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
U-100 Conversion Table (2 mL = 10 mg/mL)
| U-100 units | Volume | Contains | Yield per vial |
|---|---|---|---|
| 2 | 0.02 mL | 200 mcg | 100 injections |
| 5 | 0.05 mL | 500 mcg | 40 injections |
| 10 | 0.10 mL | 1 mg (1000 mcg) | 20 injections |
| 20 | 0.20 mL | 2 mg (2000 mcg) | 10 injections |
| 30 | 0.30 mL | 3 mg (3000 mcg) | 6 injections |
| 50 | 0.50 mL | 5 mg (5000 mcg) | 4 injections |
| 100 | 1.00 mL | 10 mg (10000 mcg) | 2 injections |
This section describes which dose a study or reference source used and what it measured. It is not a recommendation or an administration schedule. A trial dose belongs to its population, duration and supervision and does not transfer to anyone outside that context.
Supplies Needed
Straightforward 12- and 24-week planning for a 20 mg vial at 10 mg/mL.
Tesamorelin vials (20 mg each)
- Standard FDA-Approved Protocol, 12 weeks: Minimum 9 vials (161 mg required).
- Standard FDA-Approved Protocol, 24 weeks: Minimum 17 vials (329 mg required).
U-100 syringes (1 mL)
- Standard FDA-Approved Protocol, 12 weeks: 84 new syringes for 84 injections.
- Standard FDA-Approved Protocol, 24 weeks: 168 new syringes for 168 injections.
Bacteriostatic water
- Standard FDA-Approved Protocol, 12 weeks: 18 mL total (2 mL per vial) → 6 × 3 mL vials.
- Standard FDA-Approved Protocol, 24 weeks: 34 mL total (2 mL per vial) → 12 × 3 mL vials.
Alcohol swabs
- Standard FDA-Approved Protocol, 12 weeks: 168 minimum; one box of 100 does not cover the calculation.
- Standard FDA-Approved Protocol, 24 weeks: 336 minimum; one box of 100 does not cover the calculation.
Sharps container: one appropriately sized. Stability planning: totals are minimum arithmetic quantities; follow the product documentation for sterility, storage, handling loss and discard timing.
Tesamorelin 20mgView in store
Bacteriostatic water 3 mLView in storeStore links may earn a commission. A supplier page is not scientific evidence or proof of suitability for human use.
Tesamorelin Vial and Research Context
- Reconstitute: add 2 mL of bacteriostatic water to produce 10 mg/mL.
- Frequency in the source: once daily, subcutaneously.
- Described range: schedules run from 1 mg (1000 mcg) to 2 mg (2000 mcg) per injection.
- Easy measuring: 1 U-100 unit = 0.01 mL = 100 mcg.
- Vial size: the 20 mg label is total nominal content, not a per-injection amount.
- Vial coverage: at 1 mg (1000 mcg) per injection one vial supplies 20 injections; at 2 mg (2000 mcg) it supplies 10. These are mass calculations, not storage periods.
Protocol Overview
Quick reference for the schedules shared by the cited literature.
- Frequency: once daily.
- Concentration: 20 mg in 2 mL = 10 mg/mL.
- Unit conversion: 1 U-100 unit = 100 mcg.
Dosing Schedule
The tables keep each approach separate.
- Standard FDA-Approved Protocol: 1 mg (1000 mcg), 2 mg (2000 mcg), in phases (once daily).
- Measurement: use the units and mL shown beside each amount.
- Consistency: vial size does not change the schedule.
Storage Instructions
- Lyophilized (unopened): −20 °C for long-term storage; 2–8 °C if used within weeks. Protected from light.
- Reconstituted: 2–8 °C, do not freeze. Use within the documented period (typically up to 4 weeks with bacteriostatic water).
- Handling: do not shake; avoid temperature cycling; label with date and concentration.
- Discard: cloudy solutions, particulates or expired preparations are discarded.
More detail in the storage guide (Spanish).
Important Notes
- Research only: the referenced compounds are sold for laboratory research. Nothing here is medical advice or an administration schedule.
- Evidence: chart amounts come from published trials or approved prescribing information, cited in References.
- Above 100 units: a 1 mL U-100 syringe cannot hold them; split across syringes or reconstitute with less volume.
- Accuracy: concentration depends on the actual volume added; measure the diluent with a syringe, not by eye.
- Verification: confirm vial contents against the batch certificate of analysis before calculating.
Injection Technique in Research
- Route in the studies: subcutaneous, in abdominal or thigh adipose tissue, rotating the site.
- Syringe: 1 mL U-100 (100 units); read in units, not mL.
- Asepsis: alcohol swab on the stopper and the site; a new syringe per injection.
- Drawing: purge air, draw the units from the chart and verify before withdrawing the needle from the vial.
Full guide: U-100 syringes and reading units (Spanish).
Research Note
All content on this page is technical and educational. It describes how a vial is reconstituted, how a syringe is read and which amounts the cited sources describe. It does not replace the supervision of a qualified researcher or the judgment of a health professional, and it is not intended to diagnose, treat, cure or prevent any disease.
References
- Falutz J et al. N Engl J Med 2007. PMID 17984164. Dosis coincidente con la ficha técnica de Egrifta